BBP

Virtus LifeSci Biotech Products ETF

$76.50

+0.00%

Market closed. Last update: 11:42 PM ET

📎 Investment Objective

The Virtus LifeSci Biotech Products ETF (BBP) seeks to track the performance of the LifeSci Biotechnology Products Index, which is designed to provide exposure to U.S. biotechnology companies that have at least one drug product candidate in Phase II or Phase III clinical trials or have received FDA approval for at least one drug product.

Overview

ETF tracking Virtus LifeSci Biotech Products ETF

Category Technology

Issuer Other

Inception Date 2017-09-01

Market Cap $30.6M

Average Volume N/A

Dividend Yield N/A

52-Week Range $50.37 - $77.89

VWAP $76.97

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

🎯 Investment Strategy

The ETF invests in a portfolio of biotechnology companies that meet the index's criteria. The index is weighted based on market capitalization, with a cap of 4.5% per individual holding. The fund aims to provide investors with exposure to the growth potential of the biotechnology sector.

✨ Key Features

Focuses on biotechnology companies with drug candidates in late-stage clinical trials or with FDA-approved products
Diversified portfolio across the biotechnology industry
Passively managed to track the LifeSci Biotechnology Products Index
Low expense ratio of 0.00%

⚠️ Primary Risks

Biotechnology sector risk: The biotechnology industry is highly competitive and subject to rapid changes, which can impact the performance of the fund
Clinical trial and regulatory risk: Biotechnology companies face the risk of drug candidates failing in clinical trials or not receiving regulatory approval
Concentration risk: The fund is concentrated in the biotechnology sector, which may be more volatile than a more diversified portfolio
Liquidity risk: The fund may have difficulty trading certain holdings due to low trading volume or market disruptions

👤 Best For

The Virtus LifeSci Biotech Products ETF may be suitable for investors seeking exposure to the growth potential of the biotechnology sector, with a long-term investment horizon and a higher risk tolerance. The fund may be particularly appealing to investors interested in the development and commercialization of new drug products.